We won't rest until no man's diagnosis is left to chance
We won't rest until no man's diagnosis is left to chance
Movember responds to the UK’s decision on prostate cancer screening, highlighting the need for early detection, better risk assessment and vital research like TRANSFORM.
The UK National Screening Committee’s decision not to introduce routine prostate cancer screening for most men will understandably feel like a setback to many.
Prostate cancer is the most common cancer in men, and early detection saves lives – yet too many diagnoses still depend on chance.
Standing with Prostate Cancer UK
We stand firmly alongside Prostate Cancer UK, who have led the case for change and continue to push for the evidence needed to deliver a national screening program.
Their TRANSFORM trial, which Movember has proudly supported with a £1,000,000 investment, is already underway and could provide the breakthroughs required to make screening safe, effective and available to all men.
Ensuring high-risk men are not left behind
As partners across the sector highlighted today, men at higher risk – including Black men and those with a family history – cannot be left behind. Clear guidance, consistent pathways and better access to risk assessment tools are essential so men understand their risk and can take action early.
Movember’s commitment to early detection
Movember remains committed to driving progress in early detection, backing world-leading research, and ensuring men get the information, support and care they deserve.
We will not rest until no man’s diagnosis is left to chance.
Join the movement
Let’s take action. Unite to change the future of men’s health.
